Last reviewed · How we verify
ZKAB001
ZKAB001 is a small molecule drug that targets the molecular target.
ZKAB001 is a small molecule drug that targets the molecular target. Used for Unknown.
At a glance
| Generic name | ZKAB001 |
|---|---|
| Sponsor | Lee's Pharmaceutical Limited |
| Drug class | Unknown |
| Target | Unknown |
| Modality | Biologic |
| Therapeutic area | Unknown |
| Phase | Phase 3 |
Mechanism of action
ZKAB001 works by binding to the molecular target, which results in the desired therapeutic effect.
Approved indications
- Unknown
Common side effects
- Unknown
Key clinical trials
- A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLC (PHASE3)
- Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer (PHASE1)
- A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma. (PHASE1, PHASE2)
- Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic Melanoma (PHASE1, PHASE2)
- A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma (PHASE1)
- A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer (PHASE1)
- A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Recurrent or Metastatic Cervical Cancer (PHASE1)
- Study of ZKAB001 for Maintenance Therapy in Patients With High-grade Osteosarcoma After Adjuvant Chemotherapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |